FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
We now rank 3rd in pharmaceutical production by volume and 14th by value
USFDA completes PAI of Lupin’s biotech facility in Pune
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
This initiative aims to raise awareness about the importance of monitoring blood sugar levels before indulging in sweets
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
ALS patients experience neuroinflammation and rapid neurodegeneration
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
Subscribe To Our Newsletter & Stay Updated